1098O Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)

Abstract

Grade 3 (G3) NENs encompass a heterogeneous group of tumors with aggressive behaviour and poor survival. Standard front-line platinum-based chemotherapy (CT) has limited efficacy, with an ORR of 31%, a median PFS of 4-5 m and a median OS of 11 m. G3 NENs are associated with a high mutational burden and PD-L1 expression that might lead to a favorable response to immunotherapy (IT). The aim of this study is to assess the safety and potential synergy of the combination of CT plus IT in patients with advanced CT-naïve G3 NENs.